Hayley Lithwick faces ER visit after buying gray market GLP-1
Key Points:
- The rising popularity of GLP-1 weight-loss drugs has led some consumers to purchase cheaper, unapproved alternatives online, resulting in increased calls to the Georgia Poison Center and emergency room visits due to dosing errors and complications.
- About 20% of GLP-1-related calls to the Georgia Poison Center over the past two years involved unapproved "gray market" drugs, with a significant surge in calls from 38 in 2021 to 655 in 2026, representing a 1,600% increase.
- Unapproved GLP-1 products, often sold as powders requiring self-mixing, pose risks including dosing confusion, infection, and severe side effects such as prolonged vomiting and dehydration.
- Investigational drugs like retatrutide, still in clinical trials and not approved for public use, are being purchased illegally online, leading to dangerous health outcomes as consumers lack proper guidance and sterile conditions.
- Despite risks associated with unapproved drugs, patients like Hayley Lithwick report significant weight loss and improved quality of life from FDA-approved GLP-1 medications, highlighting the need for affordable, safe access.